A phase 3 clinical trial evaluating AZA + VEN vs. AZA + MAGRO in TP53-mutated AML (clinicaltrials.gov NCT04778397) and a phase 1/2 study evaluating AZA + VEN + MAGRO (clinicaltrials.gov NCT04435691) are currently enrolling. Here, TP53 is linked to acute myeloid leukemia.